Ashe Carol Gail's most recent trade in Elicio Therapeutics Inc. was a trade of 7,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elicio Therapeutics Inc. | Carol Gail Ashe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 7,900 | 7,900 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc. | Carol Gail Ashe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 4,100 | 4,100 | - | - | Stock Option (Right to Buy) | |
| Aptose Biosciences Inc | Carol Gail Ashe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 3,333 | 3,333 | - | - | Director Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc. | Ashe Carol Gail | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 4,100 | 4,100 | - | - | Stock Option (right to buy) |